About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5558879
Allelic
Composition
Fbn1tm2.1Hcd/Fbn1+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fbn1tm2.1Hcd mutation (1 available); any Fbn1 mutation (171 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• infiltration of activated B cells and plasma cells in the dermis
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• nfiltration of activated B cells and plasma cells in the dermis
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• dermal polarization towards pro-inflammatory T helper cells
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• increased IL9, IL13 and IL22 in CD3+ dermal cells
• however, auto-antibody levels are normalized by treatment with an integrin beta1 activating
• in CD3+ dermal cells
• however, auto-antibody levels are normalized by treatment with an integrin beta1 activating
• in CD3+ dermal cells
• however, auto-antibody levels are normalized by treatment with an integrin beta1 activating
• increased anti-nuclear and anti-topoisomerase I antibody levels
• however, auto-antibody levels are normalized by treatment with an integrin beta1 activating
• however, auto-antibody levels are normalized by treatment with an integrin beta1 activating

integument
• by 3 months
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• increased by 1 month
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• disorganized and excessive microfibrillar aggregates in the dermis with sparsely distributed elastin
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• decreased skin stretching (stiff skin)
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody

adipose tissue
• by 3 months
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody

hematopoietic system
• infiltration of activated B cells and plasma cells in the dermis
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• nfiltration of activated B cells and plasma cells in the dermis
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody
• dermal polarization towards pro-inflammatory T helper cells
• however, skin condition is normalized by treatment with an integrin beta1 activating or TGF-beta-neutralizing antibody

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
systemic scleroderma DOID:418 OMIM:181750
J:206074


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/19/2024
MGI 6.23
The Jackson Laboratory